Stock RO ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Roche Holding AG Swiss Exchange

Equities

RO

CH0012032113

Market Closed - Swiss Exchange
Other stock markets
 11:30:11 2024-04-19 am EDT 		5-day change 1st Jan Change
238 CHF +0.51% Intraday chart for Roche Holding AG -1.57% -8.95%
Apr. 19 Swiss Equities Flash Green; Middle East Tensions Rise MT
Apr. 19 Roche: approval in lung cancer in the United States CF

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is one of the best yield companies with high dividend expectations.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • The company's enterprise value to sales, at 3.16 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ROCHE HOLDING AG Stock Roche Holding AG
-8.95% 194B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+24.60% 672B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.08% 550B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.63% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 317B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.38% 292B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.26% 211B
B+
NOVARTIS AG Stock Novartis AG
+0.78% 203B
B-
PFIZER, INC. Stock Pfizer, Inc.
-9.69% 144B
C+
AMGEN INC. Stock Amgen Inc.
-6.63% 141B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. RO Stock
  5. Ratings Roche Holding AG